Get the Stockscreener App
96.60
6.52%
-6.74
Pre-market:
96.72
0.12
+0.12%
Glaukos Corporation stock is traded at $96.60, with a volume of 695.89K.
It is down -6.52% in the last 24 hours and down -34.01% over the past month.
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
See More
Previous Close:
$103.34
Open:
$102.8
24h Volume:
695.89K
Relative Volume:
0.91
Market Cap:
$5.31B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-32.64
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
-6.40%
1M Performance:
-34.01%
6M Performance:
-23.50%
1Y Performance:
+10.26%
1-Day Range:
$96.26
$103.28
1-Week Range:
$91.78
$106.02
52-Week Range:
$84.08
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
96.60 | 5.31B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Here's Why You Should Retain Glaukos Stock in Your Portfolio - Yahoo Finance
Glaukos Highlights Strategic Focus in 2024 Presentation - TipRanks
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution - 01Net
Glaukos, RadiusXR collaborate with Topcon Healthcare on vision testing platform - TipRanks
Glaukos Unveils Game-Changing Vision Diagnostic Wearable: First-Ever Platform for Glaucoma Testing - StockTitan
Where are the Opportunities in (GKOS) - Stock Traders Daily
US Bancorp DE Acquires 470 Shares of Glaukos Co. (NYSE:GKOS) - Defense World
Glaukos Co. (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Glaukos Corp. to Host Earnings Call - ACCESS Newswire
289 Shares in Glaukos Co. (NYSE:GKOS) Bought by IFP Advisors Inc - Defense World
Bank of New York Mellon Corp Increases Holdings in Glaukos Co. (NYSE:GKOS) - Defense World
Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts? - Insider Monkey
Glaukos, Tarsus, RxSight: Q4 Earnings Snapshot - Orange County Business Journal
Stifel maintains Buy on Glaukos stock, reiterates $175 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Glaukos stock, reiterates $175 target - Investing.com
Truist Financial Corp Sells 5,319 Shares of Glaukos Co. (NYSE:GKOS) - Defense World
7 Best Medical Technology Stocks To Buy According To Analysts - Insider Monkey
Glaukos CEO Makes a Multi-Million Dollar Stock Sale! - TipRanks
Glaukos director Mark Foley sells common stock for $2.5 million By Investing.com - Investing.com Australia
Glaukos director Mark Foley sells common stock for $2.5 million - Investing.com
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock? - MSN
Glaukos Corporation (NYSE:GKOS) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless - Simply Wall St
(GKOS) Investment Report - Stock Traders Daily
Glaukos Co. (NYSE:GKOS) Shares Sold by Taylor Frigon Capital Management LLC - MarketBeat
FDA accepts Glaukos application for Epioxa for keratoconus - MSN
CIBC Asset Management Inc Makes New Investment in Glaukos Co. (NYSE:GKOS) - Defense World
Needham & Company LLC Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock - MarketBeat
GLAUKOS Corp SEC 10-K Report - TradingView
Glaukos (NYSE:GKOS) Shares Gap Down After Earnings Miss - MarketBeat
FDA sets review date for Glaukos’ keratoconus drug By Investing.com - Investing.com Australia
GKOSGlaukos Corp Latest Stock News & Market Updates - StockTitan
FDA gives Glaukos ‘Day 74’ notice for Epioxa NDA to treat keratoconus - TipRanks
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today - Benzinga
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery - Benzinga India
Glaukos Announces FDA Acceptance Of NDA Submission For Epioxa(TM) -February 24, 2025 at 08:24 am EST - Marketscreener.com
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™ - BioSpace
FDA sets review date for Glaukos' keratoconus drug - Investing.com India
Glaukos's Corneal Disease Drug Accepted for FDA Review -February 24, 2025 at 07:33 am EST - Marketscreener.com
FDA sets review date for Glaukos' keratoconus drug By Investing.com - Investing.com South Africa
FDA sets review date for Glaukos’ keratoconus drug - Investing.com UK
Revolutionary Eye Treatment Advances: Can Glaukos Transform Keratoconus Care Without Surgery? - StockTitan
Van ECK Associates Corp Trims Position in Glaukos Co. (NYSE:GKOS) - Defense World
Glaukos (NYSE:GKOS) Price Target Raised to $160.00 - Defense World
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates - MSN
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - Defense World
Glaukos Corporation (NYSE:GKOS) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Glaukos Reports Record Sales Growth in Fourth Quarter of 2024, Announces 2025 Guidance - Vision Monday
Glaukos Q4 2024 Earnings Preview - MSN
Glaukos Corp. Reports Record Sales in Earnings Call - TipRanks
Truist maintains buy on Glaukos stock, price target steady at $185 - Investing.com Australia
Glaukos Corp earnings missed by $0.02, revenue topped estimates - Investing.com Australia
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):